Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, is pleased to announce today that it has been named as one of the 2022 Venture 50 Companies by the TSX Venture Exchange. Perimeter was the sixth-ranked company in the clean tech & life science sector with a market cap increase of approximately 79% and a share price increase of 55% in 2021.

Jeremy Sobotta, Perimeter’s Chief Executive Officer stated, “We are honored to be named as one of the Venture 50 Companies and see this recognition as further validation of the significant progress made in both the commercial and clinical development areas of our business in 2021. Our TSX Venture listing has provided Perimeter with increased awareness from both the capital and commercial markets, access to capital, and additional support to drive our business forward.”

Each year, 10 companies are selected from five key sectors, based on their performance across three equally weighted criteria – market cap growth, share price appreciation, and trading and liquidity. The TSX Venture 50 program shines a light on their successes and contributions to driving growth in the Canadian economy, creating jobs, and building shareholder value.

A video showcasing Perimeter’s ranking on the 2022 Venture 50 Companies has been posted online and is also available on the Investor section of Perimeter’s website.

Representatives from the 2022 TSX Venture 50 companies will join Loui Anastasopoulos, President, Capital Formation and Enterprise Marketing Officer, TMX Group., to virtually open the market at 9:30 a.m. ET today to celebrate this achievement. For more information on the TSX Venture 50, visit: Tsx.com/Venture50.

About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation, artificial intelligence technology that is currently under clinical development. The company’s ticker symbol “PINK” is a reference to the pink ribbons used during Breast Cancer Awareness Month.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains statements that constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. In this news release, words such as “may”, “would”, “could”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management’s future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding Perimeter’s ongoing clinical trials and product development are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter’s control. Such forward-looking statements reflect Perimeter’s current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter’s financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter’s Management Discussion and Analysis for the year ended December 31, 2020, which is available on Perimeter’s SEDAR profile at www.sedar.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

Shushu Feng Perimeter Medical Imaging AI, Inc. Direct: 647-339-7465 (PINK) Toll-free: 888-988-7465 (PINK) investors@perimetermed.com

Simplify Exchang (NYSE:PINK)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Simplify Exchang Charts.
Simplify Exchang (NYSE:PINK)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Simplify Exchang Charts.